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Abstract: 
Background & Aim: Alcohol consumption, through increasing intestinal permeability and 
causing hepatocytes damage, leads to the release of pathogen- and damage-associated 
molecular pattern molecules (PAMPs and DAMPs). These molecules stimulate hepatic 
macrophages (MΦs) and activate NF-κB, resulting in inflammation and exacerbating 
alcoholic liver disease (ALD). However, much less is known about the mechanisms 
attenuating inflammation and preventing disease progression in the majority of the heavy 
drinkers. Interleukin (IL)-33 is a DAMP (alarmin) released from dead cells and acts through 
its receptor, IL-1 receptor like 1 (ST2). ST2 signaling has been reported to either stimulate 
or inhibit NF-κB activation. The role of IL-33/ST2 in ALD has not been studied. Methods: 
Serum levels of IL-33 and its decoy receptor, soluble ST2 (sST2) were measured in ALD 
patients. Alcohol-induced liver injury, inflammation and hepatic MΦ activation were 
compared among WT, IL-33-/- and ST2-/- mice in several models. Results: Elevations of 
serum IL-33 and sST2 were only observed in patients with severe decompensated ALD. 
Consistently, in mice with mild ALD without significant amount of cell death and IL-33 
release, IL-33-deletion did not affect alcohol-induced liver damage. However, ST2-deletion 
exacerbated ALD, through enhancing NF-κB activation in liver MΦs. In contrast, when 
extracellular IL-33 was markedly elevated, both IL-33-/- and ST2-/- mice developed 
attenuated liver injury and inflammation compared with WT mice. Conclusion: Our data 
revealed a dichotomous role of IL-33/ST2 signaling during ALD development. At early and 
mild stages, ST2 restrains the inflammatory activation of hepatic MΦs, through inhibiting 
NF-κB, and plays a protective function in an IL-33-independent fashion. During severe 
liver injury, significant cell death and marked IL-33 release occur, which triggers IL-33/ST2 
signaling and exacerbates tissue damage. 
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Lay summary 
In mild ALD, ST2 negatively regulates the inflammatory activation of hepatic MΦs, thereby 
protecting against alcohol-induced liver damage, whereas in case of severe liver injury, the 
release of extracellular IL-33 may exacerbate tissue inflammation by triggering the 
canonical IL-33/ST2L signaling in hepatic MΦs.  
  
 6 
INTRODUCTION: 
Alcoholic liver disease (ALD) is a major chronic liver disorder that can progress 
from mild hepatic inflammation/injury to more severe manifestations including alcoholic 
hepatitis, cirrhosis and hepatocellular carcinoma. (1) The severe forms of ALD result in 
end-stage decompensated liver disease in approximately one third of heavy drinkers. (1, 
2) Ample evidence supports that hepatic inflammation plays a critical role in the underlying 
pathogenesis of ALD. (3) Alcohol consumption increases intestinal permeability, leading to 
the hepatic translocation of pathogen-associated molecular pattern molecules (PAMPs). In 
addition, damage-associated molecular pattern molecules (DAMPs, or alarmin) are 
released when severe injury and cell death occur (4, 5). These molecules activate NF-κB 
and stimulate inflammatory responses in liver macrophages (MΦs) and other innate 
immune cells. (6) A number of pro-inflammatory cytokines and chemokines such as TNFα, 
IL-1β, IL-6 and MCP-1 are elevated in mice fed with ethanol and in patients with ALD. (7, 
8) Targeting these cytokines has been employed as a strategy for the treatment of ALD, 
notably in alcoholic hepatitis. Neutralizing TNFα has been evaluated; however, it 
increased the risk of infection without survival benefits. (9, 10) In most inflammatory 
conditions, regulatory mechanisms play an important role in limiting the collateral tissue 
injury as result of surging in inflammatory responses. Thus, understanding the anti-
inflammatory mechanisms that attenuate TLR/NF-κB signaling during ALD is important in 
developing therapeutic strategies to prevent the progression of ALD from mild to severe 
forms.    
Interleukin (IL)-33 is a member of the IL-1 family and it is constitutively expressed 
in endothelial and epithelial cells. (11) IL-33 normally resides in the nucleus, but is 
released as an alarmin (or DAMP) upon cell death during severe tissue injury.(12) The 
receptor of IL-33 is ST2 (suppression of tumorigenicity 2), also known as IL-1 receptor 
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like-1 (IL-1rl1), is mainly expressed on various immune cells, including MΦs, type 2 T 
helper cells (Th2), mast cells and eosinophils (13-18) Similar to other IL-1 receptors, ST2 
contains an intracellular toll-interleukin-1 receptor domain (TIR), which can bind to MyD88 
and MyD88-adaptive-like (Mal). Aside from the transmembrane full length of the ST2 
receptor (ST2L), a splicing variant gives rise to a soluble form (sST2) which acts as a 
decoy receptor neutralizing extracellular IL-33 and blocking IL-33/ST2L signaling. 
Interestingly, both ST2-mediated stimulation and inhibition of NF-κB activation have been 
reported. (13-17, 19) One reason for the discrepancy is the differential ST2 signaling in the 
presence or absence of IL-33. Once released, extracellular IL-33 binds to ST2 and recruits 
IL-1 receptor accessary protein (IL-1RAcP), followed by the activation of the 
MyD88/TRAF6/NF-κB pathway. However, in the absence of extracellular IL-33 and thus 
failure of IL-1RAcP recruitment, sequestering MyD88/Mal by ST2 actually inhibits NF-κB 
activation induced by TLR agonists. (13, 19)  
The present study is the first to investigate the roles of IL-33 and ST2 in ALD. We 
observed elevations of IL-33 and sST2 in sera of patients with severe ALD. Moreover, our 
data revealed a dichotomous involvement of IL-33/ST2 signaling in animal models, 
depending on the presence or absence of substantial IL-33 release.   
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Materials and methods: 
Animal treatments 
C57Bl/6N (Taconic), IL-33-/- and ST2-/- mice (obtained from Dr. Robert B. Fick at Merck 
Research Laboratories) were maintained in ventilated cages under 12h light/dark cycle at 
the University of Colorado Anschutz Medical Campus (UCAMC) animal facility. All 
experiments were performed according to the guidelines of the IACUC at UCAMC. Ten-
week-old female mice were fed with ethanol-containing Lieber-DeCarli liquid diet to study 
ALD, and the treatment details are described in supplementary methods. 
 
Human subject cohort 
All healthy controls, heavy drinkers and ALD patients provided informed consent and the 
study were approved by the Institutional Review Board at the Richard L. Roudebush 
Veterans Administration Medical Center, Fairbanks Alcohol Rehabilitation Center and 
Indiana University Purdue University Indianapolis (IUPUI). At the time of enrollment, blood 
samples were collected and stored in -80°C freezer, until the time of analysis. The details 
about these samples are described in supplementary methods. 
 
Other methods 
Additional methods and statistical analyses are described in the supplementary methods. 
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Results: 
Serum levels of IL-33 and sST2 are significantly increased only in patients with severe 
ALD. 
Associated with severe liver damage, increased serum levels of IL-33 and sST2 
have been reported in patients with hepatitis B, acute liver failure, acute-on-chronic liver 
failure, liver cirrhosis, and hepatocellular carcinoma. (20, 21) However, the quantification 
of serum sST2 and IL-33 in ALD patients has not been reported. We obtained serum 
samples from 20 healthy individuals (age 33.2±10.6 years, 90% male, and 70% White), 20 
heavy drinkers (age 41.5±13.3 years, 65% male, and 80% White), and 11 patients with 
ALD (age 56.7±10.5 years, 90% male, and 100% White). Compared to healthy individuals, 
neither IL-33 nor sST2 was elevated in heavy drinkers, but both were markedly increased 
in ALD patients (Fig. 1A). Interestingly, there appeared to be two distinct clusters with 
differential levels of IL-33 and sST2 among subjects with ALD. Further analysis revealed 
that only patients with decompensated ALD (with Child-Pugh scores > 7) had dramatically 
higher levels of IL-33 and sST2, whereas the levels were similar among healthy 
individuals, heavy drinkers, and ALD patients with compensated livers (with Child-Pugh 
scores of 5-6, Fig. 1B). Our data demonstrate that the extracellular release of IL-33 and 
the elevation of sST2 occur in severe ALD. 
The levels of serum IL-33 and sST2 correlate with the extent of liver damage in mice 
To investigate the involvement of IL-33 and ST2 in ALD, we initially employed two 
murine models: i) chronic alcohol feeding-induced mild ALD, and ii) a recently developed 
model of more severe ALD, in which mice were fed with alcohol plus binge twice per week 
for 8 weeks (22). In agreement with the previous report (22), the ALT level remained 
modestly elevated in the model of chronic alcohol plus multiple binges (Fig. 2C), although 
higher than that in the mild ALD model (Fig. 2B&C). This suggests that dramatic cell death 
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is absent even in the advanced ALD model with worsened steatohepatitis and fibrosis. 
Consistent with the lack of marked cell death in both models, the serum levels of IL-33 
(and sST2) were not significantly increased (Fig. 2E-F), and IL-33-deletion did not affect 
alcohol-induced liver injury (Fig. 2B&C). Interestingly, the ALT levels were significantly 
higher in the ST2-/- than WT mice (Fig. 2B&C), suggesting a possible protective function of 
ST2 independent of IL-33. 
Significant amount of cell death is a pre-requisite for IL-33 release, but it does not 
occur in ALD models currently available to most of the researchers in the field. As a proof-
of-concept approach to investigate the role of extracellular IL-33, we produced more 
severe cell death by administering one low dose of CCl4 after 4 weeks of alcohol feeding. 
In this case, serum ALT activities rose to more than 2000 IU/L in WT mice (Fig. 2D). As 
result, the levels of IL-33 and sST2 increased approximately 15-fold and 8-fold, 
respectively, compared with those in mice fed with alcohol alone or alcohol plus multiple 
binges (Fig. 2E-F). Interestingly, liver injury was significantly suppressed in both IL-33-/- 
and ST2-/- mice compared with WT mice (Fig. 2D). The levels of inflammatory mediators 
were lower in the two knockout strains than WT mice (Fig. 2G). Consistent with the notion 
that extracellular IL-33 binding to ST2L triggers NF-κB activation (14-16), the data suggest 
that when there is substantial release of IL-33, the IL-33/ST2L axis exacerbates tissue 
inflammation and injury. 
ST2 attenuates chronic alcohol feeding-induced liver injury and inflammation in the 
absence of extracellular IL-33  
The clinical data showed that IL-33 was not released in patients with compensated 
ALD or in heavy drinkers without overt clinical manifestation (Fig. 1B). In mice treated with 
chronic alcohol or chronic alcohol plus multiple binges (Fig. 2E), the extracellular release 
of IL-33 was also minimal in the absence of marked cell death. As result, IL-33-deletion did 
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not affect liver injury in these two models. In contrast, ST2-deletion (in either male or 
female mice) exacerbated liver injury in both models (Fig. 2B-C and supporting Fig. S1). 
Moreover, hepatic lipid accumulation caused by chronic alcohol feeding was significantly 
higher in ST2-/- than WT mice (Fig. 3A-B). Quantification of liver triglyceride levels 
confirmed that alcohol-induced steatosis is more severe in ST2-/- than WT mice (Fig. 3C). 
Together, these data suggest that in the absence of extracellular IL-33, ST2 plays a 
protective role and perhaps serves as a regulator mechanism in attenuating ALD and 
slowing down the disease progression. 
The TLR-induced NF-κB activation is a major pathway contributing to ethanol-
induced hepatic inflammation. ST2 has been reported to inhibit TLR-mediated NF-κB 
activation. (13, 19) Therefore, we examined the role of ST2 in regulating alcohol-induced 
liver inflammation by comparing the levels of pro-inflammatory cytokines in WT and ST2-/- 
mice. As shown in Fig. 4A, although the serum levels of TNF-α were similar, the levels of 
IL-1β and IL-6 were more than 3-fold higher in ethanol-fed ST2-/- mice (18.91 ± 3.695 
pg/ml and 17.56 ± 4.149 pg/ml respectively) than in WT mice (6.077 ± 1.176 pg/ml and 
5.186 ± 1.407 pg/ml). In addition, hepatic TNF-α and IL-1β protein levels were significantly 
higher in ST2-/- than WT mice, whereas hepatic IL-6 protein levels were comparable 
between both groups (Fig. 4B).  
We further analyzed the hepatic mRNA expression levels of pro-inflammatory 
cytokines/chemokines, including IL-1α, IL-1β, TNF-α, MCP-1, IL-6 and IL-12p40. As 
shown in Fig. 4C, the levels of the majority of these pro-inflammatory mediators were 
dramatically increased in EtOH-fed compared with pair-fed ST2-/- mice. However, EtOH 
feeding only up-regulated IL-1β and IL-6 expression in WT mice. These results suggested 
that ST2-deletion augmented the inflammatory responses to chronic ethanol feeding, 
contributing to enhanced liver injury. 
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LPS causes a more severe exacerbation of alcohol-induced liver injury in ST2-/- than WT 
mice 
Alcohol-induced hepatic translocation of bacterial products is important in triggering 
hepatic inflammation through TLR signaling. As a typical TLR4 agonist, LPS has been 
used as a model system to investigate the TLR/NF-κB pathway in ALD. (23, 24) Previous 
studies have shown that LPS challenge in addition to chronic alcohol feeding exacerbates 
the degree of liver injury. (25) Based on the data described above, we hypothesized that 
ST2-/- mice might be more susceptible to liver injury and inflammation caused by chronic 
alcohol feeding plus LPS.   
To test this hypothesis, we treated EtOH-fed and pair-fed mice with 0.5 mg/kg of 
LPS after 4 weeks of feeding. Consistent with the results shown in Fig. 2B, alcohol-feeding 
alone induced higher levels of ALT in ST2-/- than WT mice. LPS challenge further elevated 
the ALT levels in both WT and ST2-/- mice. Interestingly, the effect of LPS was more 
dramatic in ST2-/- mice, as the ALT levels were almost 2-fold higher in ST2-/- mice than WT 
mice (Fig. 5A). There were no significant differences of ALT levels in pair-fed WT and ST2-
/-
 mice regardless of the additional LPS stimulation. 
Furthermore, compared with WT mice treated with ethanol plus LPS, the ST2-/- 
mice showed significantly higher serum levels of IL-1β and TNF-α (Fig. 5B). The hepatic 
mRNA expression levels of TNF-α, IL-1β, and IL-6 were compared among WT and ST2-/- 
mice treated with either pair-feeding plus LPS or EtOH-feeding plus LPS (Fig. 5C). In ST2-
/-
 mice, alcohol ingestion markedly augmented LPS-induced upregulation of these 
cytokines. Although a similar phenomenon was observed in WT mice, the combination of 
ethanol and LPS caused a much greater inflammatory response in ST2-/- mice. The data 
further confirmed the inhibitory effect of ST2 on TLR/NF-κB signaling. 
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Hepatic MΦs from ST2-/- mice exhibit an enhanced pro-inflammatory phenotype and NF-
kB activation  
Hepatic MΦs represent a major source of pro-inflammatory mediators and 
contribute to ALD. (26-28) Thus, we hypothesize that the enhanced hepatic inflammation 
observed in ethanol-treated ST2-/- mice may be due to exacerbated inflammatory 
responses of hepatic MΦs. To examine this hypothesis, we purified liver MΦs from 
ethanol-fed WT and ST2-/- mice and compared the expression levels of pro-inflammatory 
cytokines and chemokines. The levels of IL-1α, IL-1β, TNF-α, MCP-1, IL-6 and IL-12p40 
were all increased more than 10-fold in ST2-/- hepatic MΦs than WT MΦs (Fig. 6A). In 
mice treated with ethanol plus LPS, the expression levels of TNF-α, MCP-1 and IL-6 in 
hepatic MΦs from ST2-/- mice were also significantly higher than those from WT mice 
(Fig.6B). These data suggest that ST2 negatively regulates inflammatory response of 
hepatic MΦs during ALD. 
Hepatic MΦs are well-recognized as a major cell type responding to PAMPs 
translocate from the gut, as well as to DAMPs released from hepatocytes. We 
hypothesized that hepatic MΦs from ST2-/- mice are more sensitive to PAMPs/DAMPs 
stimulation than WT MΦs. Recent studies have shown that extracellular vesicles (EVs) 
which are released from hepatocytes during alcohol-induced liver injury, exert a pro-
inflammatory effect on MΦs. (29, 30) Thus, we isolated EVs from sera of WT mice 
subjected to the Gao-binge model, in which the mice were binged with EtOH after 10 days 
EtOH feeding. (31) Hepatic MΦs were isolated from chronic EtOH-fed WT and ST2-/- mice 
and stimulated with EVs. In some experiments, the cells were treated with EVs plus LPS, 
as a surrogate for PAMP. Our data showed that EVs alone or in combination with LPS 
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caused enhanced inflammatory responses in ST2-/- hepatic MΦs than WT-MΦs, evident by 
increased expression levels of IL-1β, TNFα, and MCP-1 (Fig. 6C). 
It has been shown that ST2 is not expressed in naïve MΦs, but can be induced by 
inflammatory stimulation. (13) We purified hepatic MΦs from naïve, pair-fed and ethanol-
fed WT mice to determine ST2 expression. Our data show that pair-feeding slightly 
induced ST2 expression in hepatic MΦs, but ethanol-feeding dramatically upregulated ST2 
levels in these cells (Fig. 7A). Interestingly, ethanol-feeding also induced ST2 expression 
in CD45-negative non-immune cells of the liver (Fig. 7A). However, the mRNA expression 
levels of pro-inflammatory mediators were markedly lower in CD45-negative cells than in 
hepatic MΦs (data not show), suggesting that the CD45-negative cells are not major 
players in alcohol-induced hepatic inflammation. 
 NF-κB is the key transcription factor regulating the pro-inflammatory mediators that 
were significantly upregulated in ST2-/- MΦs. To determine whether ST2 attenuates the 
inflammatory response of hepatic MΦs through suppressing NF-κB activation, we purified 
hepatic MΦs from ethanol-fed WT and ST2-/- mice. As shown in Fig. 7B, the ratio of 
phosphorylated p65 to total p65 was significantly higher in ST2-/- MΦs than WT MΦs. 
Moreover, compared with WT liver MΦs, those from EtOH-fed ST2-/- mice showed 
dramatically higher nuclear DNA binding activity of NF-κB p65 (Fig. 7C). To further 
examine whether the inhibition of ST2 promotes NF-κB-driven promoter activity, we co-
transfected WT bone marrow derived MΦs with a ST2-targeting siRNA and a NF-κB-
luciferase reporter plasmid. The data demonstrated that LPS-induced NF-κB promoter 
activity was significantly increased when ST2 was knocked down (Fig. 7D) Together, 
these data suggest that ST2 is an important negative regulator of NF-κB activation, 
thereby limiting inflammatory responses of hepatic MΦs and attenuating ALD.  
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Discussion: 
One of the important mechanisms of alcohol-induced liver injury is that alcohol or 
its metabolite, acetaldehyde, enhances gut permeability and thus promotes the 
translocation of bacterial products. In the liver, PAMPs can activate the innate immune 
cells, such as MΦs, causing pro-inflammatory responses and liver injury. The TLR and IL-
1R signaling pathways play an important role in mediating hepatic inflammatory responses 
in alcohol-induced liver injury. (23, 26) However, only about one third of heavy drinkers 
develop severe ALD, (1, 2) suggesting that there exist compensatory mechanisms 
preventing the disease progression. This study provides the first evidence that ST2 acts as 
a negative regulator of the pro-inflammatory cascades and attenuates alcohol-induced 
liver damage. Consistent with our finding, an anti-inflammatory effect of ST2 on MΦs has 
been described. (13, 19) It is reported that ST2-deficient MΦs are much more sensitive to 
bacterial lipoprotein stimulation of TLR2, evident by increased pro-inflammatory cytokine 
production and enhanced formation of TLR2-MyD88 and MyD88-IRAK complexes. (19) 
Another study demonstrates that MΦs from ST2-deficient mice produce significantly higher 
levels of pro-inflammatory cytokines in response to stimulation by a number of TLR 
agonists. (13) As result, ST2-deficient mice developed more severe inflammatory 
responses to LPS stimulation and were unable to mount endotoxin tolerance. (13) 
Regarding the underlying mechanism accounting for the anti-inflammatory function 
of ST2 during mild ALD, our data demonstrate that ST2 suppresses NF-κB activation in 
hepatic MΦs. ST2 shares a similar TIR domain as other members of the TIR family. Upon 
binding to its ligand IL-33, ST2L forms a heterodimer with IL-1RAcp, which is 
indispensable for activating NF-κB. (14-16, 32) In contrast, in the absence of extracellular 
IL-33, ST2 inhibits NF-κB activation stimulated by agonists of TLR2, TLR4 and TLR9. (13) 
This inhibition is due to sequestration of MyD88 and Mal by ST2, thereby negatively 
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regulating TLR/NF-κB signaling (Fig. 8). ST2 does not inhibit TLR3 signaling because it 
does not interact with Trif, the TLR3 adaptor. (13) These findings suggest that in the 
absence of IL-33, ST2L not only cannot signal to activate NF-κB, but also competes for 
MyD88 binding and inhibits TLR-induced NF-κB activation. (13, 19) The protective function 
of ST2 in ALD is consistent with two reported studies investigating the role of ST2 in other 
models of liver injury (33, 34). It has been shown that ST2-/- mice develop significantly 
more severe liver injury after concanavalin A treatment, with higher number of hepatic 
infiltrating leukocytes that produce higher levels of pro-inflammatory cytokines (TNFα, 
IFNγ, and IL-17). (34) A hepato-protective function of ST2 was also reported in liver 
ischemia-reperfusion (IR) injury, as blocking ST2 with anti-ST2 antibody significantly 
worsened liver damage. (33) In contrast to the marked increase of ethanol-induced hepatic 
inflammation and injury in ST2-/-, we did not observe a phenotype in IL-33-deficient mice. 
This discrepancy between IL-33-/- and ST2-/- mice can be explained by the lack of release 
of extracellular IL-33 during mild ALD. Consistent with our results, other studies have 
reported phenotypes of ST2-/- mice when extracellular release of IL-33 is negligible. (35, 
36) These findings suggest that ST2 has functions independent of IL-33. The intracellular 
IL-33 is a chromatin-associated nuclear factor, and it has been reported to act as a 
transcriptional repressor. (37) However, the fact that we do not observe a phenotype in IL-
33-/- mice suggests that the intracellular functions of IL-33 do not play a role in mild ALD 
either.  
Consistent with the notion that IL-33 is released when there is substantial tissue 
damage, we found that extracellular IL-33 was only significantly elevated in severe ALD 
patients with decompensated liver, but not in ALD patients with compensated liver nor in 
heavy drinkers. Similarly, significant IL-33 release was only observed in mice treated with 
chronic alcohol plus one low dose of CCl4, which markedly increased ALT levels, but not in 
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mouse models with low levels of ALT. Moreover, compared with WT mice, attenuated liver 
injury and inflammation were observed in both IL-33-/- and ST2-/- mice treated with alcohol 
plus a single dose of CCl4. The data suggest that when there is substantial release of IL-
33, the IL-33/ST2L axis exacerbates alcohol-induced liver injury. Taken together, our 
results suggest that ST2 signaling in MΦs differs between mild and severe ALD (Fig. 8). 
During mild ALD, extracellular IL-33 is not release. ST2L predominantly inhibits TLR-
mediated NF-κB activation and acts as a negative regulator of inflammatory responses of 
hepatic MΦs to PAMPs. This mechanism is important in attenuating ALD and may be in 
preventing/ delaying the progression of ALD from mild to severe forms. In transition from 
mild to severe ALD, the extracellular IL-33 is significantly elevated. Through binding to 
ST2L, IL-33 can trigger the formation of IL-33/ST2L/IL-1RAcP/MyD88 complex and 
activate the canonical IL-33/ST2 signaling pathway (Fig. 8), resulting in NF-κB activation 
and the production of pro-inflammatory mediators. Nonetheless, the decoy receptor, sST2 
is also produced in this case. The sST2 acts as a negative regulator of IL-33 action by 
neutralizing IL-33. In a model of liver fibrosis, it has been demonstrated that the 
extracellular IL-33 activates type 2 innate lymphoid cells through ST2L, thereby inducing 
pro-fibrogenic cytokine production and causing fibrosis. (38) Interestingly, sST2 
administration blocks the IL-33/ST2L signaling and attenuates liver fibrosis. (38) Elevated 
serum levels of IL-33 and sST2 have been reported in numerous inflammatory diseases. 
(39-41) There are eleven on-going clinical trials (clinicaltrial.gov) evaluating sST2 as a 
biomarker for several disease conditions, as many single nucleotide polymorphisms 
(SNPs) of ST2 are significantly associated with circulating sST2 levels. (42) Our study is 
the first to demonstrate significant elevations of serum levels of sST2 and IL-33 in ALD 
patients. Future studies are warranted to determine whether serum levels of IL-33, sST2 
and/or the IL-33/sST2 ratio correlate with the severity of ALD.  
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 In summary, this is the first study to elucidate the role of ST2 in the pathogenesis 
of ALD and provide insights into the differential effects of ST2 signaling in mild versus 
severe ALD (Fig. 8). Our data suggest that, during mild ALD, ST2 negatively regulates the 
inflammatory activation of hepatic macrophages, thereby protecting against alcohol-
induced liver damage. In cases of severe liver injury, the release of extracellular IL-33 may 
exacerbate tissue inflammation by triggering the canonical IL-33/ST2L signaling in hepatic 
MΦs. Although in our study, the IL-33/ST2L-antagonizing effect of sST2 appeared to be 
overridden, varying levels of sST2 in patients may be associated with disease severity. 
Thus, the ratio of IL-33/sST2 could be used a biomarker to stratify disease severity and 
predict survival outcomes in patients with ALD. 
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Figure legend: 
Figure 1: Serum levels of sST2 and IL-33 are significantly increased in patients with 
severe ALD. (A) Serum samples from healthy controls, heavy drinkers without liver 
diseases and ALD patients were collected. The levels of IL-33 (13 controls, 13 heavy 
drinkers and 10 ALD patients) and sST2 (20 controls, 20 heavy drinkers and 11 ALD 
patients) were measured by ELISA. (B) Correlation of the levels of sST2 and IL-33 with 
ALD severity based on Child Pugh classification. Those with the scores of 5-6 were 
classified as compensated ALD and those with score >7 were considered as 
decompensated liver disease. All data shown represent mean ± SEM. *p<0.05 (One-way 
ANOVA). 
 
Figure 2: Measurement of serum IL-33 and sST2 and comparing alcohol-induced 
liver injury among WT, IL-33-/- and ST2-/- female mice. (A) The dosing regimens of the 
three mouse models. Serum ALT activities (B-D), serum levels of IL-33 (E) and sST2 (F) 
were compared (n=5-15/group). *P<0.05 (One-way ANOVA) compared to various groups 
as indicated. (G) Liver NPC mRNA expression of cytokines (n=5/group). *p<0.05 (One-
way ANOVA) compared to WT mice. All data shown represent mean ± SEM. 
 
Figure 3: Chronic ethanol feeding caused increased hepatic lipid accumulation in 
ST2-/- than WT mice. Female WT and ST2-/- mice were pair-fed or EtOH-fed for 4 weeks. 
(A-B) Liver Oil Red-O staining images and quantification (n=6/group). (C) Liver triglyceride 
levels were measured (n=5-13/group). Data were analysis by 2-way ANOVA, Tukey’s 
HSD. ap<0.05 compared with EtOH-fed WT mice. bp<0.05 compared with pair-fed mice of 
the same genotype.  All data shown represent mean ± SEM. 
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Figure 4: ST2-/- mice exhibit an increased inflammatory response to chronic alcohol 
treatment. Female mice were treated as described in Figure 3. Proteins levels of pro-
inflammatory cytokines in serum (A) and EtOH-fed liver (B) were measured. Unpaired t-
test *p<0.05 compared to WT mice. Hepatic mRNA levels (C) were measured 
(n=12/group). Data were analysis by 2-way ANOVA, Tukey’s HSD. ap<0.05 compared with 
pair-fed mice of the same genotype. bp<0.05 compared with WT EtOH-fed mice. All data 
represent mean ± SEM 
 
Figure 5: LPS causes more severe exacerbation of alcohol-induced liver injury in 
ST2-/- than WT mice. Female WT and ST2-/- mice were treated with pair-fed, EtOH-fed, 
pair-fed plus LPS or EtOH-fed plus LPS. (A) Serum ALT activities were measured (n=5-
15/group). Data were analysis by 2-way ANOVA, Tukey’s HSD. ap<0.05 compared with 
WT mice of the same treatment group. bp<0.05 compared with pair-fed mice of the same 
genotype. cp<0.05 compared with mice of the same genotype and treated with the same 
feeding regimen but without LPS challenge. (B) Serum cytokine levels in WT and ST2-/- 
mice treated with EtOH plus LPS (n = 5-8/group). *p<0.05 (Unpaired t-test)  compared with 
WT mice. (C) Hepatic mRNA levels of were measured (n = 5-15/group). Data were 
analysis by 2-way ANOVA, Tukey’s HSD. ap<0.05 compared with pair-feeding plus LPS-
treated mice of the same genotype. bp<0.05 compared with EtOH-feeding plus LPS-
treated WT mice. All data shown represent mean ± SEM.  
 
Figure 6: ST2-/- hepatic MΦs exhibit an enhanced pro-inflammatory phenotype. 
Female WT and ST2-/- mice (n=9/group) were fed with EtOH for 4wks (A) and some mice 
were further challenged with LPS (B) Hepatic MΦs were isolated and mRNA expressions 
of pro-inflammatory mediators were measured. *p<0.05 (Unpaired t-test) compared with 
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WT-MΦs. (C) Hepatic MΦs isolated from EtOH-fed female WT and ST2-/- mice were 
treated with EVs in the presence or absence of LPS. EVs were isolated from sera of 
EtOH-treated WT mice. mRNA expressions of pro-inflammatory mediators were 
measured. Data were analysis by 2-way ANOVA, Tukey’s HSD. a p<0.05 compared to WT-
MΦs subjected to the same treatment. b p<0.05 compared to non-treated control MΦs of 
the same genotype. c p<0.05 compared to EV alone-treated MΦs of the same genotype. 
All data shown represent mean ± SEM. 
 
Figure 7: ST2-/- hepatic MΦs exhibit enhanced NF-κB activation. (A) ST2 message 
levels were measured in hepatic MΦs and CD45-negative cells by RT-PCR. Hepatic MΦs 
were isolated from female EtOH-fed WT and ST2-/- mice. (B) The expression levels of p65 
and phosphorylated p65 were measured by Western blot. *p<0.05 (Unpaired t-test) 
compared with WT-MΦs. Results shown represent 3 independent experiments of total 9 
mice per group. (C) DNA-binding activities were measured using an NF-κB p65 
transcription factor activity kit. Control samples (CTL) include a negative CTL without 
proteins, a positive CTL using pure NF-κB p65, and another CTL using dsDNA to compete 
for DNA-binding. *p<0.05 (Unpaired t-test) compared with WT-MΦs (n=4/group). (D) WT 
bone marrow derived-MΦs were co-transfected with a NF-κB luciferase reporter gene 
construct and either scrambled siRNA or ST2 siRNA. Luciferase activities in the absence 
or presence of LPS stimulation were measured. Results are from three separate 
experiments, each performed in triplicate. Data were analysis by 2-way ANOVA, Tukey’s 
HSD. *p<0.05 compared with scrambled siRNA-treated controls. All data shown represent 
mean ± SEM. 
 
Figure 8: Schematic for the roles of ST2 in mild versus severe ALD. 
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In mild ALD, extracellular release of IL-33 is minimal. In the absence of IL-33, ST2L does 
not form heterodimers with IL-1RAcp (interleukin-1 receptor-associated protein) and thus 
does not activate NF-κB. Instead, ST2L sequesters MyD88 and competes with TLR for 
MyD88 binding, thereby attenuating TLR-induced signaling and NF-κB activation. In 
severe ALD, substantial cell death causes significant accumulation of extracellular IL-33. 
Binding of IL-33 to ST2L recruits IL-1RAcp and induces down-stream signaling, thereby 
activating NF-κB and promoting pro-inflammatory responses. However, during severe 
ALD, sST2 is also released, which acts as a decoy receptor blocking the IL-33/ST2L 
signaling. Therefore, the ratio of IL-33/sST2 may be an important indicator for the degrees 
of hepatic inflammation and injury during severe ALD. (PAMP, pathogen-associated 
molecular pattern; IRAK, IL-1R-associated kinase; TRAF6, TNFR-associated factor 6, IL-
1RAcp, interleukin-1 receptor-associated protein) 
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